Shots:
- The CHMP has recommended Imreplys (sargramostim) to treat pts of all ages with Haematopoietic Sub-syndrome of Acute Radiation Syndrome (H-ARS) following myelosuppressive radiation exposure, across the EU, Norway, Iceland, and Liechtenstein
- Sargramostim is a recombinant human GM-CSF produced using yeast (S. cerevisiae) expression technology
- In 2018, the same formulation was approved by the US FDA as a brand name: Leukine (Partner Therapeutics)
Ref: PRNewswire | Image: Partner Therapeutics | Press Release
Related News:- BeOne Receives CHMP Positive Opinion for New Brukinsa Tablet Formulation Across All Approved Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
